Coachella Valley Behavioral Health Hosts Ceremony to Celebrate Grand Opening
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest acute care hospital, Coachella Valley Behavioral Health, located at 81555 JFK Court in Indio, California. A ribbon-cutting ceremony was held today to mark its grand opening with…
Working to address modern slavery
alk Free’s 2023 Global Slavery Index estimates that almost 50 million people around the world are being coerced, threatened or deceived in order to be exploited and have their freedom undermined. Modern slavery is a broad term that includes human…
Top private health insurance claims for 2023
Medibank has released data on the top hospital claims for 2023, as well as the most expensive claims paid this year. Medibank can reveal that the highest paid claim was $321,000 for neonatal services, with a $274,000 claim for tracheostomy…
IPA Announces Closing of $1.265 Million Public Offering of Common Shares
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), today announced the closing of its $1.265 million underwritten public offering of 1,265,000 common shares, including 165,000 common shares issued pursuant to the full exercise by the underwriter of…
RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation
RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a 20-patient pilot clinical trial to examine the safety and efficacy of the company’s bone adhesive biomaterial called TETRANITE® to immediately stabilize and fixate…
bluebird bio Announces FDA Approval of LYFGENIA for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or “bluebird”) today announced the U.S. Food and Drug Administration (FDA) has approved LYFGENIA™ (pronounced as ‘lif-JEN-ee-uh’) (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12…
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor…
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant…
BostonGene Named to the 2023 CB Insights’ Digital Health 50 List
CB Insights named BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, to its fifth-annual Digital Health 50 showcasing the 50 most promising private digital health companies of 2023. The 50 winners, representing eight countries across the globe, were selected from…
NextGen Healthcare’s UGM23 Inspires Attendees with Transformative, AI-Driven Physician and Patient Solutions
Thousands of ambulatory healthcare professionals from across the US traveled to Orlando last week to gather insights on navigating the ever-changing healthcare landscape, including how to leverage artificial intelligence (AI) to reduce provider burnout and maximize outcomes. Held Nov. 29…
European Commission Approves Pfizer’s ELREXFIO for Relapsed and Refractory Multiple Myeloma
–Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab). ELREFXIO is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior…
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating Plus LENVIMA as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by…